| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_13a7ac0e215a10ef98bce7136c7a35be
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_821aba440890ea2dd058a77b98eafa65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_03dd1795b2b843fd51658322cdf5c23d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0d02da6a228f83f2c7fa55bc994ffeaf |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2848
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2006-08-22^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2e67417554c5c1140f87012fea07bf6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac1645ecb445ba04926d307c05a0edcc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba6bdb7cb33fb7adf3928bc901d27d1b |
| publicationDate |
2007-03-01^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2007024921-A2 |
| titleOfInvention |
Combination therapies for inhibiting integrin-extracellular matrix interactions |
| abstract |
The present application relates to compositions of extracellular matrix (ECM) antagonists and their use in methods for treating angiogenic-dependent conditions. The ECM antagonists can bind the same or different ECM component. The present application also relates to compositions of ECM antagonists and cancer therapies and their use in methods for preventing, treating or managing angiogenic- dependent conditions such as cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8759009-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014151917-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10081673-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8580928-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11216881-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009023411-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10997659-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10614520-B2 |
| priorityDate |
2005-08-24^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |